Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-24. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Low BMD === Bone Mineral Density (BMD) tends to peak at a young age. When children are younger, they start building up their BMD through their nutrition and through exercise. BMD peaks at around 12.5 years old for girls and around 14 years old for boys. It could be caused by a deficiency in calcium or Vitamin D. Calcium is the main nutrient for bone health. It aids in the structure and density of the bone. Low BMD could be caused by the children not getting the proper exercise for adequate bone growth. Researchers suggest that children should get 20 minutes of vigorous activity 3 to 5 days a week to promote an increase in BMD. Jumping for about 5 minutes a day also stimulates an increase in BMD. Researchers did a 10-year study on the effects of vigorous intensity activity and their bone health/strength. They studied 300 boys and girls. They found that in boys going through puberty (ages 11-13), they experienced a greater bone mass growth. Their bone mass increased during this time because their bones are not ready for the mechanical stress from them growing. However, that is how the bones grow stronger and why their BMD increases. Too much stress on the bones could cause BMD to decrease. Low BMD is dangerous because it can cause disorders inside the bone as the children grow and get older. These disorders can cause the bone to ossify, become brittle, fragile, more easily prone to fractures, and weak. Some of these disorders include osteopenia, osteoporosis, and scoliosis. Scoliosis is very common in children. Low BMD plays a role in the child's scoliosis.
In a group of chronic high-dose ketamine users, the frequency of liver injury was reported to be about 10%. There are case reports of increased liver enzymes involving ketamine treatment of chronic pain. Chronic ketamine abuse has also been associated with biliary colic, cachexia, gastrointestinal diseases, hepatobiliary disorder, and acute kidney injury.
==== Human evolution ==== During the long period between one and three million years ago, the Australopithecine (ancestors of modern humans) underwent several evolutionary changes. A long-term climate shift toward drier conditions promoted life changes from sedentary forest-dwelling with a primarily plant-based diet toward upright walking/running on open terrain and more meat consumption. One consequence of the shift to a culture that included more physically active hunting was a need for evaporative cooling from sweat, which to be functional, meant an evolutionary shift toward less body hair, as evaporation from sweat-wet hair would have cooled the hair but not the skin underneath. A second consequence was darker skin. The early humans who evolved in the regions of the globe near the equator had permanent large quantities of melanin in their skin, resulting in brown/black skin tones. For people with light skin tone, exposure to UV radiation induces the synthesis of melanin causing the skin to darken, i.e., sun tanning. Either way, the pigment can protect skin by dissipating up to 99.9% of absorbed UV radiation. In this way, melanin protects skin cells from UVA and UVB radiation damage that causes photoaging and the risk of melanoma, a cancer of melanin cells. Melanin also protects against photodegradation of the vitamin folate in skin tissue and, in the eyes, preserves eye health. The dark-skinned humans who had evolved in Africa populated the rest of the world through migration some 50,000 to 80,000 years ago.
Sources: en.wikipedia.org
Asymmetric warfare – Araucanian leaders such as Lautaro developed effective military tactics to counter the Spanish invasion, winning the Arauco War. These tactics consisted in a combination of espionage, cattle raiding, and using attack waves in the battlefield to exhaust the enemy. Astronomy – Mesoamerican cultures, such as the Maya and Aztec, were able to accurately predict astronomical events, like eclipses, hundreds of years into the future. Atlatl – Paleo-Indians (Beringian Diaspora) from over 11,500 years ago had developed a highly developed spear thrower in the form of the atlatl to hunt woolly mammoths, giant sloths, mastodon, muskox (euceratherium), giant beaver, early caribou, steppe bison, saber-toothed cat, and other Pleistocene animals. Using the atlatl, these ancient Paleo-Indians were able to traverse much of the Americas from Alaska, down to Mexico, Central America, South America, and, finally, all the way south into Chile as they hunted and followed these Pleistocene megafauna within a short 3,000 year time period–from about 14,500 years ago to about 11,500 years ago. Avocado – Indigenous Americans were the first to domesticate and cultivate avocados.
==== MeSH D13.444.600 – nucleic acid probes ==== MeSH D13.444.600.150 – antisense elements (genetics) MeSH D13.444.600.150.200 – DNA, antisense MeSH D13.444.600.150.200.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.600.150.640 – oligonucleotides, antisense MeSH D13.444.600.150.640.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.600.150.640.645 – oligoribonucleotides, antisense MeSH D13.444.600.150.760 – rna, antisense MeSH D13.444.600.150.760.640 – oligoribonucleotides, antisense MeSH D13.444.600.223 – DNA probes MeSH D13.444.600.223.500 – DNA, complementary MeSH D13.444.600.223.550 – DNA probes, hla MeSH D13.444.600.223.555 – DNA probes, hpv MeSH D13.444.600.601 – oligonucleotide probes MeSH D13.444.600.723 – rna probes MeSH D13.444.600.723.480 – rna, complementary
== Variation == Many genetic variants of the GC gene are known. They produce 6 main haplotypes and 3 main protein variants (Gc1S, Gc1F and Gc2). The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels. They have been proposed to account for some of the differences in vitamin D status in different ethnic groups, and have been found to correlate with the response to vitamin D supplementation.
=== 2024: United Cup champion, two Masters titles and French Open final === Alongside Team Germany, Zverev competed and won the United Cup, saving two championship points in his singles match against Hubert Hurkacz and defeating Team Poland in the final. In Melbourne, he reached the quarterfinals of the 2024 Australian Open, defeating Dominik Koepfer, Lukas Klein for his 400th career win, Alex Michelsen, and Cameron Norrie, with two matches requiring deciding set tiebreakers. He then achieved his first-ever win against a top-5 player at a Grand Slam, defeating Carlos Alcaraz in four sets in the quarterfinals, to make his first Australian Open semifinal appearance since 2020. He subsequently lost to Danill Medvedev, despite being two sets to love up. His defeat marked only his second loss from being up two sets to love in a 5-set match, his first being against Dominic Thiem in the final of the 2020 US Open. In Mexico, Zverev reached the semifinals in Los Cabos with straight sets wins against Yoshihito Nishoka and Thanasi Kokkinakis but lost to Jordan Thompson in a deciding set tiebreaker. In Acapulco, Zverev lost to Daniel Altmaier in the first round. Seeded sixth at the BNP Paribas Open, Zverev reached the quarterfinals for the first time since 2021, defeating Christopher O'Connell, Tallon Griekspoor, and Alex de Minaur before losing to eventual champion Carlos Alcaraz. Seeded fourth at the Miami Open, Zverev reached the semifinals, defeating Félix Auger-Aliassime, Christopher Eubanks, Karen Khachanov, and Fábián Marozsán before losing to Grigor Dimitrov.
Sources: en.wikipedia.org
=== Toxicity === Overdose from dietary sources alone is unlikely because excess magnesium in the blood is promptly filtered by the kidneys. Overdose is more likely in the presence of impaired renal function. Overdose is likely in cases of excessive intake of supplements. Megavitamin therapy has caused death in a child, and severe hypermagnesemia in a woman and a young girl who had healthy kidneys. The most common symptoms of overdose are nausea, vomiting, and diarrhea; other symptoms include hypotension, confusion, slowed heart and respiratory rates, deficiencies of other minerals, coma, cardiac arrhythmia, and death from cardiac arrest. Inhalation of magnesium oxide in industrial settings can cause metal fume fever.
Symptomatic coeliac disease (characterised by symptoms related to gluten) can be further categorised into classical and non-classical. Classical coeliac disease, which in the past has also been called typical coeliac disease, is coeliac disease presenting with malnutrition, malabsorption, and diarrhoea. Non-classical coeliac disease, historically referred to as atypical coeliac disease, is when individuals primarily present with symptoms unrelated to malabsorption. Potential coeliac disease refers to those who have positive serology for coeliac disease but no changes in the small intestine. The term latent coeliac disease has been used interchangeably with potential coeliac disease, but has no consistent definition, and its use is therefore discouraged. Sometimes, those with coeliac disease will continue to experience symptoms or signs of the disease despite being on a gluten-free diet. "Slow responders" or "non responsive coeliac disease" (NRCD) is the persistence of symptoms despite exclusion of gluten for 6 to 12 months. Refractory coeliac disease (RCD) is the persistence of malabsorption and damage to the small intestine after at least 12 months of a gluten-free diet. Most people with NRCD do not have RCD; instead, their symptoms are caused by some other factor. There are two types of RCD: type one has histopathological changes similar to those seen in untreated coeliac disease, whereas type two has abnormal histopathological changes not consistent with untreated coeliac disease.
=== Awards received in the 2000s === COLACRO (Congreso Latinoamericano de Cromatografia) Merit Medal; Pittsburgh Analytical Chemistry Award; Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry; Tracy M. Sonneborn Award for Outstanding Research and Teaching, Indiana University; Dal Nogare Award in Chromatography; CaSSS (California Separation Science Society) Award for Excellence in Separation Science; Honorary Member of the Slovak Pharmaceutical Society; Foreign Member of the Learned Society of the Czech Republic (Czech Academy of Sciences); American Chemical Society Award in Analytical Chemistry; Jan Weber Prize and Medal, Slovak Pharmaceutical Society, Slovakia; Ralph N. Adams Award in Bioanalytical Chemistry.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.